Cardiovascular Systems Inc (NASDAQ:CSII) Director Martha Goldberg Aronson purchased 3,000 shares of the business’s stock in a transaction on Thursday, November 1st. The stock was acquired at an average cost of $28.72 per share, with a total value of $86,160.00. Following the completion of the acquisition, the director now directly owns 3,000 shares in the company, valued at approximately $86,160. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
CSII stock opened at $32.60 on Thursday. The company has a quick ratio of 4.03, a current ratio of 4.54 and a debt-to-equity ratio of 0.16. Cardiovascular Systems Inc has a one year low of $20.58 and a one year high of $40.00. The stock has a market cap of $1.13 billion, a price-to-earnings ratio of 652.00 and a beta of 2.36.
Cardiovascular Systems (NASDAQ:CSII) last posted its quarterly earnings data on Tuesday, October 30th. The medical device company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.03). Cardiovascular Systems had a net margin of 0.36% and a return on equity of 0.62%. The firm had revenue of $56.27 million for the quarter, compared to analysts’ expectations of $55.96 million. Sell-side analysts predict that Cardiovascular Systems Inc will post -0.09 EPS for the current year.
A number of equities research analysts have weighed in on CSII shares. Zacks Investment Research downgraded shares of Cardiovascular Systems from a “hold” rating to a “strong sell” rating in a report on Wednesday, September 12th. BidaskClub downgraded shares of Cardiovascular Systems from a “buy” rating to a “hold” rating in a report on Saturday, September 22nd. Stifel Nicolaus started coverage on shares of Cardiovascular Systems in a report on Wednesday, August 22nd. They issued a “buy” rating and a $45.00 price target for the company. Needham & Company LLC reissued a “hold” rating on shares of Cardiovascular Systems in a report on Wednesday, October 31st. Finally, Lake Street Capital reissued a “buy” rating and issued a $50.00 price target on shares of Cardiovascular Systems in a report on Wednesday, August 1st. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $35.20.
TRADEMARK VIOLATION WARNING: This news story was posted by WKRB News and is the sole property of of WKRB News. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://www.wkrb13.com/2018/11/08/insider-buying-cardiovascular-systems-inc-csii-director-buys-86160-00-in-stock.html.
About Cardiovascular Systems
Cardiovascular Systems, Inc, a medical device company, develops, manufactures, and commercializes various devices to treat vascular and coronary diseases in the United States. The company offers peripheral arterial disease products, including Diamondback 360 Peripheral, Predator 360, Stealth 360 Peripheral Orbital Atherectomy System (OAS), Diamondback 360 60cm Peripheral OAS, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral, Diamondback 360 2.00 Peripheral, Diamondback 360 200cm Peripheral, and Diamondback 360 180cm Peripheral, which are catheter-based platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives.
See Also: Marijuana Stocks
Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.